Literature DB >> 16971802

Tolerogenic dendritic cells: the ins and outs of outcome.

Bao-Guo Xiao1, Yu-Min Huang, Hans Link.   

Abstract

Recent studies point to an important role for dendritic cells (DCs) in the induction of peripheral tolerance, revealing that the maturation and/or activation state of DCs might be a control point for the induction of peripheral tolerance. Recent progress in our understanding of the mechanisms mediating immune tolerance indicates them to be far more complex than hitherto anticipated. Factors deciding the outcome of vaccination with autologous DCs to prevent and treat diseases with an autoimmune background include maturation state of DCs, their administration route, long-term effects, antigen loading, and in vivo microenvironment. DC vaccination, although promising, is far from standardized. In this review, we discuss the ins and outs of DC-mediated immune tolerance and the need for careful experimental design to unequivocally prove the efficacy and reach the goal of optimized use of DCs in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971802     DOI: 10.1097/01.cji.0000210387.55951.8b

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

1.  Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice.

Authors:  Gautam Sule; Masataka Suzuki; Kilian Guse; Racel Cela; John R Rodgers; Brendan Lee
Journal:  Hum Gene Ther       Date:  2012-05-11       Impact factor: 5.695

Review 2.  Poly-N-acetyl glucosamine gel matrix as a non-viral delivery vector for DNA-based vaccination.

Authors:  Mohamed L Salem; Marina Demcheva; William E Gillanders; David J Cole; John N Vournakis
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

Review 3.  Dendritic cells in intestinal homeostasis and disease.

Authors:  Maria Rescigno; Antonio Di Sabatino
Journal:  J Clin Invest       Date:  2009-09-01       Impact factor: 14.808

4.  Expression and function of immunoglobulin-like transcripts on tolerogenic dendritic cells.

Authors:  Juan Wu; Anatolij Horuzsko
Journal:  Hum Immunol       Date:  2009-05       Impact factor: 2.850

5.  Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases.

Authors:  Peter Terness; Thilo Oelert; Sandra Ehser; Jing Jing Chuang; Imad Lahdou; Christian Kleist; Florian Velten; Günter J Hämmerling; Bernd Arnold; Gerhard Opelz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-18       Impact factor: 11.205

6.  Comparative study of clinical grade human tolerogenic dendritic cells.

Authors:  M Naranjo-Gómez; D Raïch-Regué; C Oñate; L Grau-López; C Ramo-Tello; R Pujol-Borrell; E Martínez-Cáceres; Francesc E Borràs
Journal:  J Transl Med       Date:  2011-06-09       Impact factor: 5.531

7.  Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer.

Authors:  Felicita Baratelli; Hiroko Takedatsu; Saswati Hazra; Katherine Peebles; Jie Luo; Pam S Kurimoto; Gang Zeng; Raj K Batra; Sherven Sharma; Steven M Dubinett; Jay M Lee
Journal:  J Transl Med       Date:  2008-07-22       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.